Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Ultomiris approved in Japan for aHUS in adults and children

Sep. 29, 2020

No Comments

Dimerix reports phase II data on DMX-200 in diabetic kidney disease

Sep. 14, 2020

No Comments

Bayer initiates enrollment in phase II CONCORD study of runcaciguat

Sep. 10, 2020

No Comments

First subject dosed in phase I study of ALLN-346

Sep. 9, 2020

No Comments

Akebia reports topline data from its PRO2TECT global phase III program of vadadustat

Sep. 4, 2020

No Comments

Tohoku University divulges dioxolan derivatives for renal diseases

Sep. 2, 2020

No Comments

Ardelyx divulges glycyrrhetinic derivatives for hyperkalemia

Sep. 1, 2020

No Comments

Taisho Pharmaceutical discloses new 20-HETE synthase inhibitors

Aug. 31, 2020

No Comments

Evotec and Novo Nordisk collaborate to develop novel therapies for CKD

Aug. 19, 2020

No Comments

AstraZeneca is enrolling participants in phase I study of MEDI-8367

Aug. 7, 2020

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

BioWorld Science, Nephrology
RSS

Ultomiris approved in Japan for aHUS in adults and children

Dimerix reports phase II data on DMX-200 in diabetic kidney disease

Bayer initiates enrollment in phase II CONCORD study of runcaciguat

First subject dosed in phase I study of ALLN-346

Akebia reports topline data from its PRO2TECT global phase III program of vadadustat

Tohoku University divulges dioxolan derivatives for renal diseases

Ardelyx divulges glycyrrhetinic derivatives for hyperkalemia

Taisho Pharmaceutical discloses new 20-HETE synthase inhibitors

Evotec and Novo Nordisk collaborate to develop novel therapies for CKD

AstraZeneca is enrolling participants in phase I study of MEDI-8367

Today's news in brief

Today's news in brief

Regulatory actions for Oct. 31, 2024

Nanocube’s nanorobots to revolutionize cancer diagnosis, treatment

Cureverse, Angelini ink $360M deal for oral Alzheimer’s drug

BioWorld Science, Nephrology RSS

BioWorld Science, Nephrology
RSS